BACKGROUND: Screening over many years is required to optimize reductions in colorectal cancer (CRC) mortality. However, no prior trials have compared strategies for obtaining long-term adherence. METHODS: Systems of Support to Increase Colorectal Cancer Screening and Follow-Up was implemented in an integrated health care organization in Washington State. Between 2008 and 2009, 4675 individuals aged 50 to 74 years were randomized to receive the usual care (UC), which included clinic-based strategies to increase CRC screening (arm 1), or, in years 1 and 2, mailings with a call-in number for colonoscopy and mailed fecal tests (arm 2), mailings plus brief telephone assistance (arm 3), or mailings and assistance plus nurse navigation (arm 4). Active-intervention subjects (those in arms 2, 3, and 4 combined) who were still eligible for CRC screening were randomized to mailings being stopped or continued in years 3 and 5. The time in compliance with CRC screening over 5 years was compared for persons assigned to any intervention and persons assigned to UC. Screening tests contributed time on the basis of national guidelines for screening intervals (fecal tests annually, sigmoidoscopy every 5 years, and colonoscopy every 10 years). RESULTS: All participants contributed data, but they were censored at disenrollment, death, the age of 76 years, or a diagnosis of CRC. Compared with UC participants, intervention participants had 31% more adjusted covered time over 5 years (incidence rate ratio, 1.31; 95% confidence interval, 1.25-1.37; covered time, 47.5% vs 62.1%). Fecal testing accounted for almost all additional covered time. CONCLUSIONS: In a health care organization with clinic-based activities to increase CRC screening, a centralized program led to increased CRC screening adherence over 5 years. Longer term data on screening adherence and its impact on CRC outcomes are needed. Cancer 2017;123:4472-80.
INTRODUCTION
Despite the potential for colorectal cancer (CRC) screening to reduce CRC mortality, CRC remains the second leading cause of cancer deaths in the United States. 1 In 2017, an estimated 135,000 adults in the United States will be diagnosed with CRC, and 50,000 will die of it. 1 Better treatments have improved survival, but morbidity and mortality could be more rapidly and cost-effectively reduced with higher uptake of and adherence to CRC screening. 2 Multiple studies have demonstrated that mailing fecal tests increases CRC screening uptake, but almost all such studies have evaluated screening after only a 1-time intervention. [3] [4] [5] [6] [7] [8] [9] [10] [11] There is little information on whether an ongoing mailed program improves screening adherence over time, particularly in a setting in which patients also have access to screening colonoscopy and flexible sigmoidoscopy. Long-term adherence to fecal testing might not be as robust as adherence to the other tests because of its annual testing cycle versus testing every 5 or 10 years.
Information on longer term adherence to mailed fecal-testing programs comes from organized programs, but these studies lack a comparison group. [12] [13] [14] [15] Systems of Support to Increase Colorectal Cancer Screening and Follow-Up (SOS) is an ongoing trial that, between 2008 and 2009, randomized age-eligible patients not current for CRC screening to either the usual care (UC) or 1 of 3 stepped-intensity interventions: mailings (including mailed fecal tests), mailings plus brief telephone assistance, or mailings and assistance plus nurse navigation. 16 The UC group had access to clinic-based screening strategies but no organized program for mailing fecal tests. We previously demonstrated that in comparison with individuals receiving UC, individuals randomized to the stepped-intensity interventions were 25% (arm 2), 31% (arm 3), or 38% (arm 4) more likely to be adherent to CRC screening in both years of the 2-year study (all P < .001). 17 Our a priori hypothesis was that in comparison with UC, exposure to any SOS intervention would lead to increased time in compliance with CRC screening guidelines over 5 years.
MATERIALS AND METHODS
The study data presented here were collected from August 2008 to November 2014 with support from a grant from the National Cancer Institute. 18 The study procedures were approved by the institutional review board. The methods, recruitment, and results of the parent 2-year study have been published and are briefly described here. 17, 19, 20 
Participant Enrollment
The setting is 21 primary care medical centers owned by Kaiser Permanente Washington (formerly Group Health Cooperative), an integrated health care system in Washington State. SOS is a randomized controlled trial of 4675 patients who at study enrollment were 50 to 74 years old and were due for CRC screening (no colonoscopy within 9 years, no flexible sigmoidoscopy within 4 years, and no fecal test within 9 months). The initial enrollment included mailing letters to 15,451 potentially eligible patients on the basis of electronic health record (EHR) and claims data (collectively called EHR-linked data), and this was followed by a telephone call to confirm eligibility (no prior CRC, inflammatory bowel disease, or lifethreatening illnesses) and a willingness to participate. Those verbally agreeing were mailed study information (no written consent was required).
After the 2-year trial ended, participants received letters asking them whether they wanted to continue study participation with an opt-out number to call. Participants who left the health plan, were diagnosed with CRC, were older than 75 years, or died were ineligible for continued participation. Figure 1 provides a diagram of the participation status over the 5-year analysis.
Randomization
Participants were stratified by clinic, age (50-64 vs 65-74 years), and self-reported prior CRC testing. A computer program generated random allocation sequences. The study database automatically randomized enrolled individuals within each stratum with a permuted block design, with the randomization concealed. Investigators remained blinded to outcomes by randomization group until the 5-year data collection was complete.
UC
At the time of this study, the US Preventive Services Task Force and Group Health recommended CRC screening by annual fecal testing, flexible sigmoidoscopy every 5 years, or colonoscopy every 10 years. 21 UC at Group Health between 2008 and 2009 involved clinic-based strategies to promote CRC screening, including a letter received annually at the time of the patient's birthday and signed by his or her physician that provided information on overdue tests, including CRC screening. In addition, beginning in 2010, Group Health's primary care medical centers were certified as patient-centered medical homes (PCMHs). Medical assistants at PCMHs determined whether, at the time of a clinic visit, a patient was overdue for recommended screening tests, immunizations, or care for chronic conditions. If a patient was overdue for CRC screening, he or she was provided with a fecal test, or the provider discussed ordering colonoscopy. The PCMHs also included outreach activities: medical assistants reviewed a registry with lists of their physician's patients with a birthday that month, called patients to remind them of needed care, and could mail fecal-testing kits to patients overdue for screening. The completeness of outreach activities, including reminder calls and the mailing of fecal-testing kits, varied by clinic and medical assistant/ physician teams. 22 In 2010, Group Health switched from a high-sensitivity 3-sample guaiac kit (Hemoccult SENSA; Beckman Coulter, Brea, California) to a 1-sample fecal immunochemical test (OC FIT-CHECK; Polymedco, Cortland Manor, New York). SOS switched tests at the same time as Group Health.
Interventions

Year 1 and 2 interventions
Participants were randomized to receive either UC (arm 1) or 1 of 3 stepped-care interventions described briefly here (additional information is provided in the online supporting information): an EHR-linked, automated, mailed program that included information on CRC screening choices, a number to call for colonoscopy or flexible sigmoidoscopy if preferred, and mailed fecal tests for those not calling (automated; arm 2); automated mailings plus, for those still unscreened, brief phone assistance from a medical assistant to complete their CRC screening test choice (assisted; arm 3); or the automated mailings Long-Term Adherence to CRC Screening/Green et al Cancer and assistance plus, for those still unscreened, ongoing support from a nurse navigator for overcoming screening barriers (navigated; arm 4). Year 1 and 2 study results have been published. 17 
Years 3 and 5
Participants who had originally been randomized to the automated, assisted, or navigated arms (arms 2-4), were still CRC screening-eligible (ie, they had not completed a colonoscopy), had not opted out of participation, were still enrolled in Group Health, were not older than 75 years, and were without a positive fecal test were rerandomized in year 3 to automated, mailed interventions being either continued or stopped (see online supporting information); the same computer-based and concealment methods used in the initial study were used. Randomization to stopped or continued mailings occurred on the date on which patients were due for their third round of annual screening (if they were still eligible for screening as described previously) rather than the third anniversary of initial randomization. Thus, the numbers are different than those based on the initial randomization and presented in Table 3 .
c Participants were censored during the 5-year follow-up period for the following reasons: disenrollment from the health plan (n 5 1107), discontinuation of the study (n 5 81), age > 75 year (n 5 132), CRC diagnosis (n 5 19), death (21) , and other ineligibility condition (n 5 31). CRC indicates colorectal cancer; Y1, year 1; Y2, year 2; Y3, year 3; Y4, year 4; Y5, year 5.
Year 3 randomization was stratified by the prior randomization arm, the clinic, and whether the participant had completed a fecal test in year 1 or 2. Stopped-arm patients no longer received study interventions. Year 3 study results have been published. 23 Year 3 mailed interventions were repeated in year 5 for continued-arm patients who were still eligible. There were no interventions in year 4 because of the interval between initial and continued funding. Additional information about usual care and the active interventions can be found on supporting table 1 [see online supporting information]).
Outcome Definitions
The primary outcome was defined as the proportion of follow-up time in compliance with CRC screening guidelines over 5 years: participants randomized initially to UC (arm 1) were compared with those initially randomized to any of the active-intervention arms (arms 2, 3, and 4 combined) in years 1 and 2, regardless of whether they were randomized in year 3 to stopped or continued interventions in years 3 and 5 ( Fig. 1) . The follow-up time was defined as the total number of days of study follow-up from randomization to the end of 5 years or a censoring event. Censoring occurred at disenrollment, study withdrawal, death, the age of 76 years, or a CRC diagnosis. In agreement with screening guidelines, we defined the number of days in compliance (the covered time) by giving 1, 5, and 10 years of screening coverage credit from the date of completion of fecal, flexible sigmoidoscopy, and colonoscopy testing, respectively, until the end of study follow-up. If coverage periods from repeated testing overlapped, coverage during the overlap period was attributed to the earlier test. CRC test completion was determined from EHR-linked data. Because these administrative data sources contained insufficient information to distinguish between screening and diagnostic tests, outcome measures were based on CRC testing, regardless of the indication.
Analysis
We used Poisson regression to estimate the primary outcome, the covered time, with the number of covered days as the dependent variable and the number of follow-up days as the offset parameter. The offset parameter allowed the estimation of the rate of adherence (the proportion of the observed time for which participants were adherent) for censored participants, who had various lengths of followup time. As a binary indicator, the intervention group (UC vs any active intervention) was included in the model to estimate treatment effects. Models were adjusted for age, sex, race, and education. The secondary outcome of interest was whether a participant received any CRC test over 5 years. Poisson regression was used, with a binary indicator for any testing used as the dependent variable and with the number of follow-up days used as the offset parameter; the models were adjusted for the same covariates used in the covered-time analysis. Interaction terms between the randomization group (UC vs any intervention group) and the baseline age (50-64 vs 65-74 years), sex, education, race/ ethnicity (non-Hispanic white vs nonwhite or Hispanic), and CRC screening before SOS participation were added to the model to test for differences in intervention effects on the primary outcomes by these subgroups. Each interaction was evaluated in a separate model.
Exploratory analyses were conducted to better understand the testing patterns during the 5 years of follow-up. For each study year, we defined 2 annual measures of compliance: the percent covered time in the past year and the cumulative covered time since randomization. Both measures were partitioned into covered time due to fecal testing, flexible sigmoidoscopy, and colonoscopy, with the mean percent covered time plotted by year. An additional exploratory analysis examined testing completed during each study year by those still in need of screening. This differed from the covered-time analysis because it assessed new testing (ie, it did not give credit for testing in prior years) in the subset of the population still in need of screening and not censored. Poisson models with binary testing indicators as the dependent variable and with days of follow-up in the study year as the offset parameter were used to assess the significance of intervention effects on annual testing metrics.
RESULTS
The analytic sample comprised 4653 participants contributing CRC testing data (Fig. 1) , with 3262 of 4653 (70.1%) contributing 5 years of complete data. For those censored, the most common reason was health plan disenrollment (n 5 1107), with others censored because they had died (n 5 21), had reached the age of 76 years (n 5 132), had received a CRC diagnosis (n 5 19), or had opted out of participation (n 5 81). No difference arose between the intervention and UC groups in the percentage with censoring events (30.1% and 29.2%, respectively) or in the average length of follow-up (4.23 and 4.25 years, respectively). The 2 groups were similar in age, sex, race/ethnicity, insurance type, self-rated general health, marital status, education, and prior CRC screening history (Table 1) .
On average, the percent covered time was greater among intervention-group participants (62.1%; 95% confidence interval [CI], 61.0%-63.2%) than UC participants (47.5%; 95% CI, 45.5%-49.5%; adjusted rate ratio, 1.31; 95% CI, 1.25-1.37; P < .001; Table 2 ). Almost all additional coverage was due to increased fecal testing, with the intervention arm completing significantly more fecal tests in every year except year 4, when no interventions were offered ( Table 3 ). The intervention group was also significantly more likely to have completed at least 1 CRC test in comparison with the UC group (85.7% vs 76.4%; P < .001) over 5 years or until censoring.
The largest differences in fecal testing occurred in years 1 and 2, the 2 years in which some intervention patients received stepped-intensity interventions (Table  3 ). Net differences in fecal testing were smaller in years 3 and 5 when half of the year 1 and 2 intervention participants who were still eligible for CRC screening were randomized to interventions being stopped (n 5 1106), with the other half (n 5 1102) continuing to receive only mailed interventions. By year 5, after the transition from guaiac testing to fecal immunochemical testing, the percentage of UC patients still eligible for CRC screening who completed fecal testing was almost double that of years 1 and 2. Despite these changes, the rate of fecal test completion in years 3 and 5 was significantly greater for the combined intervention group versus the UC group. Figure 2 shows the cumulative covered time and the annual covered time by year and by test type. Early colonoscopies and flexible sigmoidoscopies contributed to covered time in ensuing years. Because of early differences in screening rates between the 2 groups and less overall screening in the UC group, the cumulative covered time remained lower for the UC group than the intervention group over the 5-year period ( Fig. 2A) . Differences in covered time in the past year were greatest in years 1 and 2 but persisted in later years (Fig. 2B) .
Intervention effects did not differ significantly by patient characteristics. Nonsignificant increases in intervention effects on the covered time arose among the Abbreviations: CRC, colorectal cancer; GED, general educational development; SD, standard deviation. Data were missing for race/ethnicity (n 5 27), general health status (n 5 6), marital status (n 5 7), education (n 5 4), and family history (n 5 72). a The usual-care group included all participants who were randomized to the usual-care arm in year 1 and received no active interventions over 5 years. b The intervention group included participants who were randomized to any of the 3 active interventions in years 1 and 2, and it included both subgroups randomized in year 3 to interventions being stopped or continued. Abbreviations: CI, confidence interval; IRR, incidence rate ratio.
Poisson models with the follow-up time as an offset parameter were used; they were adjusted for age, sex, race, and education. a The usual-care group included all participants who were randomized to the usual-care arm in year 1 and received no active interventions over 5 years. b The intervention group included participants who were randomized to any of the 3 active interventions in years 1 and 2, and it included both subgroups randomized in year 3 to interventions being stopped or continued. 
DISCUSSION
Our study demonstrated that an ongoing and centralized mailed intervention resulted in participants being adherent to CRC screening guidelines more than 30% more of the time in comparison with UC participants over 5 years, and it increased the percentage of patients who received any testing by almost 10%. Currently, the debate continues over the relative benefit of annual fecal testing versus colonoscopy. Trials using an endpoint of CRC mortality are underway. [24] [25] [26] A potential advantage of colonoscopy is that it provides years of coverage, whereas fecal testing needs to be repeated annually. However, individuals may delay undergoing colonoscopy and may spend time being unprotected without any type of testing. In addition, many individuals will not complete colonoscopy because of personal preferences or limited access due to their geographic location or a lack of insurance coverage. [27] [28] [29] Thus, the need for fecal testing is likely to continue, If a participant had undergone a combination of fecal tests, flexible sigmoidoscopy, or colonoscopy, a fecal test was counted only if it had been the first test. Sigmoidoscopy and colonoscopy were always counted unless both occurred, in which case only the first was counted. Participants were eligible for screening in a year if they had not undergone flexible sigmoidoscopy or colonoscopy or had been censored in a prior year. In a given year, a participant might have undergone both colonoscopy and flexible sigmoidoscopy and been censored. a P values were taken from separate Poisson models with the follow-up time as an offset parameter; models were adjusted for age, sex, race, and education; separate models were fit for each test type, limited to those eligible for screening in a given year. b Intervention effects on the completion of flexible sigmoidoscopy by year were not tested because of the low participation rates. c Participants who had a diagnosis of colorectal cancer, had died, had reached the age of 76 years, or had disenrolled from the health plan were censored.
particularly for low-income and nonwhite populations, for whom the barriers to undergoing colonoscopy may be the greatest. 28 Fecal testing provides a greater benefit when it is performed annually; evidence shows that the sensitivity for cancer detection improves with repeat testing, with some cancers missed in one year but found in the following year. 30 Our study demonstrates that a centralized program providing ongoing support (primarily mailed fecal tests) increases long-term adherence to fecal testing and CRC screening overall.
We know of no other studies reporting the percentage of the time that people were current for CRC screening. The Minnesota Colon Cancer Control Study (1976) (1977) (1978) (1979) (1980) (1981) (1982) (1983) (1984) (1985) (1986) (1987) (1988) (1989) (1990) (1991) (1992) , one of the trials that established the efficacy of the fecal occult blood test (FOBT) in decreasing CRC mortality and incidence, reported adherence rates greater than 70% for 11 mailed FOBT screening rounds. 31, 32 Colonoscopy was not offered. Large population-based screening programs provide additional information about adherence to multiple rounds of mailed FOBTs. Jensen et al 33 reported that in the initial year of a centralized mailed fecal immunochemical testing program, 48.2% of 670,841 completed mailed fecal immunochemical testing kits. Of those completing the initial test, 75.3% to 86.1% completed additional tests each of the 3 following years. In Scotland, among 251,578 eligible adults, the rates of adherence to mailed fecal testing were 55%, 45%, and 48% in years 1, 2, and 3, respectively.
14 In the Netherlands, among 23,339 participants, adherence to 3 rounds of biennial fecal immunochemical testing ranged from 60% to 63%, with 72% participating at least once and 48% participating in all rounds. 15 Fewer populationbased data are available for colonoscopy adherence. In the Nordic-European Initiative on Colorectal Cancer Study, of 31,420 participants randomized to colonoscopy screening, 40% completed testing. 34 Although these studies provide information on the level of adherence that large-scale programs may achieve over time, they provide no information on the combined contributions of different CRC screening options.
Published quality metrics such as the Healthcare Effectiveness Data and Information Set provide crosssectional information on CRC screening rates. Mehta et al 35 reported that CRC screening rates at Kaiser Permanente Northern California increased after the implementation of fecal immunochemical testing and a centralized mailed program from 35% in 2004 to more than 81% in 2013 versus 62% nationally. 36 These reports provide no information on the percentage of the time that participants were compliant with screening or the percentage never tested and no comparisons between a clinic-based approach and the addition of a centralized program.
Modeling studies have examined the effect of adherence on the effectiveness of different CRC screening strategies. In a report to the US Preventive Services Task Force, Knudsen et al 37 estimated that a 50% increase in adherence would lead to a proportionate increase in lifeyears gained. Effective strategies for increasing screening uptake have been promoted by the Community Preventive Services Task Force and, in a systematic review, by the Agency for Healthcare Quality and Research. 38, 39 Recommendations include the use of clinician and client reminder systems and small media (eg, videos, letters, and brochures). Resources for implementing these strategies are available through the National Colorectal Round Table, the National Cancer Institute's Cancer Control Planet, and Research-Tested Intervention Programs, but there is little to inform which strategies lead to long-term adherence to CRC screening recommendations. 40 Winawer et al 41 called for evidence-based strategies to ensure ongoing adherence to CRC testing; they pointed out that most CRC screening in the United States is opportunistic and is offered at clinic visits only. EHRs can provide alerts at clinic visits. However, individuals needing their next CRC test at a date after the visit and those with infrequent visits might become overdue. We also previously demonstrated that the centralized approach is cost-saving. 42 Our study has limitations. Our patients all had health insurance, were mostly white and non-Hispanic, and had higher levels of education than the US population. Thus, our findings may be less generalizable to other populations. Participants also provided verbal consent in year 1 and, therefore, were volunteers, who may be more responsive to interventions. 20 Our outcome included CRC tests regardless of the indication (ie, screening or diagnostic). However, because we would not expect major differences in diagnostic testing across groups, it is reasonable to attribute the observed differences between groups to screening. 43 Lastly, our study is complex. Our initial study tested adherence to screening over 2 years, and intervention patients were rerandomized to mailed interventions being stopped or continued in years 3 and 5. Not accounting for this in our analysis makes our estimates conservative. We combined the stopped and continued groups and compared them with the UC group. Had we continued interventions in all intervention patients and in year 4, covered-time differences likely would have been greater.
In conclusion, our study is the first randomized controlled trial to demonstrate that a centralized mailed screening program increases adherence to guidelinerecommended CRC screening over 5 years. The centralized program also significantly decreased the proportion of eligible individuals with no CRC testing over 5 years. Longer term data on CRC screening adherence and its impact on CRC outcomes are needed.
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